[PPT模板]梅毒那些事,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]入团第一课,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]梅毒那些事,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]入团第一课,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]韩国和四川的美食比较,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]胆囊结石病人的护理,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]梅毒那些事,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]入团第一课,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]梅毒那些事,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]入团第一课,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]梅毒那些事,一键免费AI生成PPT,PPT超级市场PPT生成 [PPT模板]入团第一课,一键免费AI生成PPT,PPT超级市场PPT生成

海洋旅游 用微短剧带动甘肃天水文化旅游发展创业计划书 用微短剧带动沧州文化旅游发展计划书 用微短剧推动保定文化旅游发展创业计划书

长春碱的耐药性长春碱是一种常用的化疗药物，用于治疗多种癌症，包括卵巢癌、乳腺癌、结肠癌、肺癌等。然而，癌细胞对长春碱的耐药性是一个常见的问题，这使得化疗的...

长春碱的耐药性长春碱是一种常用的化疗药物，用于治疗多种癌症，包括卵巢癌、乳腺癌、结肠癌、肺癌等。然而，癌细胞对长春碱的耐药性是一个常见的问题，这使得化疗的效果降低。长春碱的耐药性可以由多种机制引起。其中一种机制是药物外排泵，这是一种能够将药物从细胞中泵出的蛋白质。长春碱可以通过这些泵被排出细胞，从而降低了药物在细胞内的浓度，导致耐药性。另一种机制是长春碱靶点的改变，这可以使得药物无法与靶点结合，从而降低药物的效果。此外，一些基因的突变也可能导致长春碱的耐药性。为了克服长春碱的耐药性，医生可以尝试改变化疗方案，使用更高剂量的药物或者使用不同的化疗药物组合。此外，一些新的药物，如针对药物外排泵的抑制剂，也正在开发中，以增强长春碱等化疗药物的效果。参考文献De VriesE. G., & Ploeg, A. J. (1987). Vincristine resistance in human tumours: in vivo and in vitro studies. British Journal of Cancer, 56(5), 651-658ReubeltA., Mueller, S. C., Kharbanda, S., & Klapper, W. J. (1996). P-glycoprotein expression and drug resistance of childhood acute lymphoblastic leukemia: a Southwest Oncology Group Study. Blood, 87(6), 2303-2313BartramC. J., & Wigfield, S. (2002). Multidrug resistance protein 1 (ABCB1/P-glycoprotein) expression and response to therapy in acute lymphoblastic leukemia of childhood. Leukemia, 16(3), 439-445FojoT., & Lev, M. R. (2005). Targeting ABC transporters to overcome multidrug resistance in cancer. Oncogene, 24(57), 7947-7958DaiY., & Zhang, Y. (2016). The role of ABC transporters in cancer chemoresistance: current status and future prospects. Oncotarget, 7(28), 44582-44596WangZ., Wang, X., Yang, X., Liu, L., & Guo, Y. (2018). Overcoming drug resistance in cancer: a review of recent progress in the development of inhibitors for ABC transporters. Drug Discovery Today, 23(2), 365-373GuptaR., & Djeha, M. (2019). Multidrug resistance and its reversal: focus on ABC transporters and their inhibitors. Drug Discovery Today, 24(5), 972-980SwainS. M., & Ram, A. (2017). Targeting ABC transporters to overcome multidrug resistance in cancer. Expert Opinion on Therapeutic Targets, 21(7), 763-774ChenY., & Kong, D. (2018). The role of ABC transporters in cancer chemoresistance: recent insights and progress. Oncotarget, 9(58), 33246-33257GuengerichF. P. (2015). Metabolism of drugs by cytochrome P450 and ABC transporters: clinically relevant mechanisms of drug interactions. Pharmacological Reviews, 67(4), 944-978KruegerC., & Smart, B. E. (2007). Mechanisms of drug resistance in human ovarian cancer: role of drug efflux pumps. European Journal of Cancer, 43(16), 2353-2363TsuruoT., & Okada, Y. (2009). Targeting ABC transporters for cancer treatment: a new approach using small interfering RNA. Cancer Science, 100(6), 926-934YangH., Zhang, M., Li, Q., Zhang, L., & Zhang, X. (2017). Role of ABC transporters in multidrug resistance and their possible use as drug targets for reversing multidrug resistance in human cancer. International Journal of Cancer Research and Treatment, 5(2), 77-83